Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years

NCT00845429 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00845429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00845429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
November 30, 2008
Enrollment
729 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, myxovirus infection, orthomyxoviruses